Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dornase alfa Clear all
Completed Phase 3 Interventional Results available

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

NCT04402970
View directory record Official record
Conditions
SARS-CoV 2, ARDS
Interventions
Dornase Alfa Inhalation Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 4, 2026, 6:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

DNase Treatment for Dry Eyes

NCT02193490
View directory record Official record
Conditions
Dry Eye
Interventions
DNase, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 4, 2026, 6:19 AM EDT
Withdrawn Phase 1 Interventional

Pulmozyme for Sjogren's Associated Cough

NCT01357447
View directory record Official record
Conditions
Sjogren's Syndrome, Cough
Interventions
Dornase alfa, Saline
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 4, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 4, 2026, 6:19 AM EDT
Terminated Not applicable Interventional

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

NCT05392855
View directory record Official record
Conditions
Cystic Fibrosis, Mucociliary Clearance Defect
Interventions
Symptom driven performance of airway clearance, Continuous daily performance of airway clearance
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 4, 2026, 6:19 AM EDT
Completed No phase listed Observational Results available

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

NCT04378153
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

NCT00671723
View directory record Official record
Conditions
Atelectasis
Interventions
Normal saline:, Hypertonic Saline, Dornase alpha
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 6:19 AM EDT
Withdrawn Phase 3 Interventional

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme single use ampule, placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional

Use of DNAse in Neutrophilic Asthma

NCT03994380
View directory record Official record
Conditions
Neutrophilic Asthma
Interventions
RhDNAse Inhalation Solution
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

NCT00416182
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme (dornase alfa), Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Fibrinolytic Therapy Versus Medical Thoracoscopy

NCT03213834
View directory record Official record
Conditions
Pleural Diseases
Interventions
Chest thoracoscopy, Chest fibrinolytic therapy, tPA, DNase
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 4, 2026, 6:19 AM EDT
Not listed Phase 1 Interventional

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

NCT02135588
View directory record Official record
Conditions
Loculated or Non-draining Malignant Pleural Effusions
Interventions
Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 4, 2026, 6:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518
View directory record Official record
Conditions
Ocular Graft vs Host Disease, Dry Eye
Interventions
rhDNase I, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 4, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

Rethinking Early Airway Clearence Therapies

NCT07696338
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
As-needed hypertonic saline (HS), Twice daily hypertonic saline (HS), As-needed dornase alfa (DA), Daily dornase alfa (DA)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
3 Years to 16 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Study of Pulmozyme to Treat Severe Asthma Episodes

NCT00169962
View directory record Official record
Conditions
Asthma
Interventions
rhDNAse (pulmozyme)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 4, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285
View directory record Official record
Conditions
Covid19
Interventions
Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
Drug
Lead sponsor
Jon Simmons
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 4, 2026, 6:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Understanding of Experiences With the SIMPLIFY Trial

NCT04320381
View directory record Official record
Conditions
Cystic Fibrosis, Drug Withdrawal
Interventions
Qualitative Interview
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 4, 2026, 6:19 AM EDT
Not listed Phase 2 Interventional

Pulmozyme to Improve COVID-19 ARDS Outcomes

NCT04402944
View directory record Official record
Conditions
COVID
Interventions
Pulmozyme, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 4, 2026, 6:19 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

NCT00434278
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Dornase alfa, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
14 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 4, 2026, 6:19 AM EDT
Not listed Early Phase 1 Interventional

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

NCT00536952
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pulmozyme, Placebo, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 4, 2026, 6:19 AM EDT
Completed No phase listed Observational

Dornase Alfa Administered to Patients With COVID-19 (DACOVID)

NCT04387786
View directory record Official record
Conditions
COVID-19, Mechanical Ventilation
Interventions
Dornase Alfa
Drug
Lead sponsor
Feinstein Institute for Medical Research
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 4, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276
View directory record Official record
Conditions
Atelectasis, Ventilation, Mechanical
Interventions
Pulmozyme (nebulized dornase alpha), Saline
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 4, 2026, 6:19 AM EDT